Thomas P Young

Summary

Affiliation: Abbott Laboratories
Country: USA

Publications

  1. ncbi Prevalence, mutation patterns, and effects on protease inhibitor susceptibility of the L76V mutation in HIV-1 protease
    Thomas P Young
    Abbott Molecular, 1300 East Touhy Avenue, Des Plaines, IL 60018 3315, USA
    Antimicrob Agents Chemother 54:4903-6. 2010
  2. ncbi Performance of the Abbott RealTime HIV-1 viral load assay is not impacted by integrase inhibitor resistance-associated mutations
    Thomas P Young
    Abbott Molecular, 1300 East Touhy Avenue, Des Plaines, IL 60018 3315, USA
    J Clin Microbiol 49:1631-4. 2011

Collaborators

Detail Information

Publications2

  1. ncbi Prevalence, mutation patterns, and effects on protease inhibitor susceptibility of the L76V mutation in HIV-1 protease
    Thomas P Young
    Abbott Molecular, 1300 East Touhy Avenue, Des Plaines, IL 60018 3315, USA
    Antimicrob Agents Chemother 54:4903-6. 2010
    ..L76V was associated with a 2- to 6-fold decrease in susceptibility to lopinavir, darunavir, amprenavir, and indinavir and a 7- to 8-fold increase in susceptibility to atazanavir and saquinavir...
  2. ncbi Performance of the Abbott RealTime HIV-1 viral load assay is not impacted by integrase inhibitor resistance-associated mutations
    Thomas P Young
    Abbott Molecular, 1300 East Touhy Avenue, Des Plaines, IL 60018 3315, USA
    J Clin Microbiol 49:1631-4. 2011
    ..5). The differences in viral load measurements between assays were comparable in the two groups, demonstrating that the RealTime HIV-1 assay can tolerate raltegravir-selected mutations...